Taiwan Advance Bio-Pharmaceutical Inc.
Taiwan Advance Bio-Pharmaceutical Inc. operates in the biotechnology industry in China, Germany, USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, India, Pakistan, and internationally. The company provides food safety diagnostic testing kits; ELISA, rapid, and chemical test kits customization, and food safety lab establishment consultation services; and manufactures monoclonal and… Read more
Taiwan Advance Bio-Pharmaceutical Inc. (4186) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.001x
Based on the latest financial reports, Taiwan Advance Bio-Pharmaceutical Inc. (4186) has a cash flow conversion efficiency ratio of 0.001x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$197.00K) by net assets (NT$252.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Taiwan Advance Bio-Pharmaceutical Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Taiwan Advance Bio-Pharmaceutical Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Taiwan Advance Bio-Pharmaceutical Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Taiwan Advance Bio-Pharmaceutical Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zelluna ASA
OL:ZLNA
|
-1.736x |
|
Ege Seramik Sanayi ve Ticaret AS
IS:EGSER
|
-0.103x |
|
Tamawood Ltd
AU:TWD
|
0.051x |
|
Fleming Properties AB
ST:FLMNG
|
0.040x |
|
Samchuly Bicycle Co. Ltd
KQ:024950
|
0.163x |
|
ZINNWALD LITHIUM LS -01
F:7WW
|
N/A |
|
TOUBF
PINK:TOUBF
|
-0.160x |
|
Welltend Technology Corp
TW:3021
|
0.027x |
Annual Cash Flow Conversion Efficiency for Taiwan Advance Bio-Pharmaceutical Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Taiwan Advance Bio-Pharmaceutical Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$256.44 Million | NT$8.33 Million | 0.032x | -39.75% |
| 2023-12-31 | NT$233.92 Million | NT$12.61 Million | 0.054x | +164.03% |
| 2022-12-31 | NT$244.64 Million | NT$-20.59 Million | -0.084x | +57.73% |
| 2021-12-31 | NT$241.45 Million | NT$-48.08 Million | -0.199x | -42.02% |
| 2020-12-31 | NT$358.90 Million | NT$-50.33 Million | -0.140x | +39.09% |
| 2019-12-31 | NT$654.80 Million | NT$-150.75 Million | -0.230x | -- |